1	Vaginal estrogen therapy initiation after breast cancer and oncological outcomes: a
2	nationwide population-based target trial emulation.
3	
4	Short title
5	Oncologic safety of vaginal estrogen therapy after breast cancer
6	
7	Authors
8	Elise Dumas ^{1,2} , Anne-Sophie Hamy ^{2,3} , Paul Gougis ² , Enora Laas ⁴ , Floriane Jochum ^{2,5} , Diane
9	Hill ⁶ , Christine Rousset-Jablonski ⁷ , Sophie El Ferjaoui ⁸ , Philippe-Jean Bousquet ^{9,10} , Sophie
10	Houzard ¹¹ , Christine Le Bihan-Benjamin ¹¹ , Fabien Reyal ^{2,4,12} , Kerollos Nashat Wanis ¹³ , Mats
11	Julius Stensrud ^{1*} , Florence Coussy ^{2,8*}
12	
13	* Authors contributed equally.
14	
15	Affiliations
16	¹ Institute of Mathematics, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
17	² Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department,
18	INSERM, U932 Immunity and Cancer, Université Paris Cité F-75005 Paris, France
19	³ Institut Curie, Medical Oncology, Universite Paris Cite, 26 rue d'Ulm, 75005 Paris, France
20	⁴ Department of Surgical Oncology, Universite Paris Cite, Paris, 75005, Paris, France
21	⁵ Department of gynecology, Strasbourg University Hospital, Strasbourg, France
22	⁶ Service de gynécologie médicale à l'hôpital Port royal - Cochin du Pr Plu Bureau, Université Paris cité
23	⁷ Département de chirurgie oncologique, Centre Léon Bérard, 28, Promenade Léa-et-Napoléon-
24	Bullukian, 69008 Lyon, France; Service de Gynécologie-Obstétrique, Hospices Civils de Lyon, Hôpital
25	Femme Mère Enfant, 59 boulevard Pinel, 68500 Bron, France; Université Claude Bernard Lyon 1, EA
26	1290 RESHAPE RESearch in HealthcAre PErformance, 8, avenue Rockefeller, 69008 Lyon, France. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- ⁸Department of Medical Oncology, Institut Curie, University of Paris, 75005 Paris, France
- ⁹Aix Marseille Univ, Inserm, IRD, SESSTIM, Equipe Labellisée Ligue Contre le Cancer, 13005
- 29 Marseille, France
- 30 ¹⁰Survey Data Science and Assessment Division, French National Cancer Institute (Institut National du
- 31 Cancer INCa), 92100 Boulogne-Billancourt, France
- 32 ¹¹Health Data and Assessment, Survey Data Science and Assessment Division, French National Cancer
- 33 Institute (Institut National du Cancer INCa), 92100 Boulogne-Billancourt, France
- ¹²Department of Surgery, Institut Jean Godinot, Reims, France
- 35 ¹³Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center,
- 36 Houston, TX, USA
- 37

38 Corresponding author

- 39 Dr Elise DUMAS
- 40 École Polytechnique Fédérale de Lausanne (EPFL)
- 41 Institute of Mathematics
- 42 Station 3 CH-1015 Lausanne, Switzerland
- 43 <u>elise.dumas@epfl.ch</u>
- 44
- 45 Number of words: 3,500

46 Key words: breast cancer, vaginal estrogen therapy, disease-free survival, target trial

47 emulation, causal inference

48 Acknowledgments

- 49 We thank the Department of Health Data and Assessment, Health Survey Data Science and
- 50 Assessment Division, French National Cancer Institute (Institut National du Cancer INCa) for
- 51 providing us with access to the cancer cohort.

52 Abstract

53 Background: Genitourinary syndrome of menopause (GSM) frequently occurs after breast 54 cancer (BC), leading to symptoms that can severely affect quality of life. Vaginal estrogen 55 therapies (VETs), including compounds like promestriene and estriol, are recommended for 56 GSMs. However, there is concern that VETs might affect the risk of BC relapse in women with 57 a history of BC.

58 **Material and Methods:** Utilizing data from the French National Health Data System, we 59 emulated target trials to investigate the effect of VET initiation (promestriene or estriol) on 60 disease-free survival (DFS) in women with a history of non-metastatic BC. Trials were 61 emulated sequentially at 12, 24, 36, and 48 months after BC diagnosis. We estimated survival 62 probabilities at three and five years and used inverse probability weights to adjust for 63 confounders.

Results: Of the 136,408 unique patients meeting the inclusion criteria for at least one the 64 65 emulated trials, 1,737 (1.3%) initiated VET. In patients with hormone receptor (HR)-positive 66 tumors treated with tamoxifen, the estimated difference in DFS for VET initiation versus no 67 initiation was 0.2 percentage-point at five years (95% CI -4.1; 3.6), while it was -2.9 (95% CI 68 -6.5; 0.0) in patients with HR-positive tumors treated with aromatase inhibitors. In this 69 subgroup, the estimated difference in DFS for promestriene initiation versus no VET initiation 70 was -2.5 percentage-points at five years (95% CI -6.7; 1.1) while it was -3.7 (95% CI -10.1; 71 1.8) for estriol initiation versus no VET initiation; and the differences between the two 72 molecules were even more pronounced at three years.

Discussion: Our results do not find evidence that VET decreases DFS in patients with *HR*positive tumor treated with tamoxifen. However, VET initiation might decrease DFS in patients
treated with aromatase inhibitors, with estriol leading to a more pronounced decrease in DFS
than promestriene.

77 Introduction

Breast cancer (BC) is the most frequent cancer in women, with approximately 2·3 million cases reported annually [1]. Due to the high incidence of BC around menopausal age and the common use of endocrine therapy as adjuvant treatment, BC survivors often experience symptoms associated with declining estrogen levels [2], including genitourinary syndrome of menopause (GSM). GSM is primarily characterized by vaginal dryness, itchiness, burning, overactive bladder, urinary incontinence or infection, sexual symptoms, and significantly impaired quality of life [3].

85

86 Vaginal estrogen therapies (VETs) are currently the main recommended treatment for the management of GSMs [4,5]. Available molecules include conjugated equine estrogens, 87 88 estradiol (E2), estriol (E3), the final metabolite of estrogen synthesis, and promestriene, a 89 synthetic estrogen-based VET. While all of these formulations are approved as pharmacologic 90 interventions for the treatment of isolated moderate-to-severe GSM in healthy women [6,7], 91 their availability varies worldwide. For example, promestriene is available in some European 92 countries, such as France, but not in the United States. In case of history of BC, both the U.S. 93 Food and Drug Administration and European Medicines Agency formally contraindicate the 94 use of VET. However, most national and international guidelines, albeit cautious, endorse the use of VET after BC as a second-line intervention in case of non-hormonal treatments failure, 95 96 with shared decision making between the oncologist and the patient [7-10].

97

98 Systemic administration of estrogen can lead to BC relapse [11]. Indeed, the rationale for 99 prescribing endocrine therapy (ET) is to block estrogen pathways, either by reducing estrogen 100 synthesis or by competitive linkage with estradiol receptors. However, current literature 101 evaluating the effect of topical VET on oncological outcomes in patients with previous BC has

102 yielded inconsistent results. The reported effect of VETs on serum estradiol levels varied 103 according to studies, with some studies finding increased estradiol levels [12,13] while others 104 did not find changes [14–16]. From an epidemiological view, most observational studies found 105 no significant association, or a positive association, between VET use after BC and BC 106 prognosis [17–25]. However, two studies found an increased risk of relapse in the subgroup of 107 patients treated with aromatase inhibitors (AIs) in patients using VETs [24,25]. So far, no 108 randomized controlled trial has been conducted to evaluate the safety of VET after BC with 109 recurrence as a primary endpoint, leaving open the question of the safety of VET utilization 110 after BC.

111

Previous observational studies relied on classical statistical methods and were not designed to answer causal questions. In contrast, target trial emulation has been recently developed and popularized as a framework for designing observational studies that aim to quantify effects of interventions [26,27]. This approach consists of designing the observational study analysis to mimic key features of a hypothetical target randomized controlled trial in which the interventions would be compared, thereby reducing the risk of fundamental design flaws and highlighting potential sources of bias that could result in spurious causal conclusions.

119

120 In this study, we used data derived from one of the largest population-based resources available

121 so far - the French National Health Data System [28,29] - to emulate target trials investigating

122 the effect of VET initiation during BC follow-up on disease-free survival (DFS).

123 Material and methods

124 125

Data source, ethics, and data protection

We used nationwide data from the previously published retrospective French Early Breast 126 127 Cancer Cohort (FRESH) cohort [30], which was released from the French administrative health 128 care database, SNDS (Système National des Données de Santé) within the Oncology Data 129 Platform available at the French National Cancer Institute [28,29]. The FRESH cohort includes 130 all women 18 years and older, with non-metastatic BC newly diagnosed between January 1, 2011, and December 31, 2017. Details about the cohort constitution and the data available have 131 been previously published [30] and are provided in the Supplementary Notes. The study was 132 133 conducted in collaboration between Institut Curie and the French National Cancer Institute 134 (INCa), following institutional and ethical rules concerning research involving patient data, 135 and was authorized by the French data protection agency (Commission nationale de 136 l'informatique et des libertés—CNIL) under registration number 920017. No informed consent 137 was required because the data used in the study was de-identified.

138

140

139

Hypothetical target trial design

141 We begin by defining a hypothetical target randomized controlled trial that would allow us to 142 identify effects of VETs on relevant clinical outcomes. Inclusion criteria for the hypothetical 143 target trial were (i) being a woman with a history of non-metastatic BC, treated at least by breast surgery and any systemic treatment (chemotherapy, targeted therapy, or endocrine 144 145 therapy), (ii) being 70 years of age or younger, (iii) not having a history of BC recurrence, and 146 (iv) not having used VET within the 2 years before target trial inclusion. In the hypothetical 147 target trial, individuals were randomly assigned to one of two arms: (i) initiation of VET 148 (treatment arm), or (ii) no initiation of VET (control arm). The trial endpoint was disease-free 149 survival (DFS), defined as the time, in months, from BC diagnosis to death, loco-regional

150 recurrence, contralateral recurrence or distant recurrence, whichever occurred first. The causal 151 estimand of interest was the average treatment effect (ATE) of initiating VET, which could be 152 estimated by the difference in DFS probabilities in the two arms at three years and five years 153 after trial inclusion. Subgroup analyses with respect to hormone receptor (HR) status and type 154 of endocrine therapy (ET) were conducted. 155 156 Emulation using observational data 157 158 We next describe how the hypothetical target trial was emulated using the SNDS data. The 159 emulation step involves matching the conditions specified in the hypothetical target trial as 160 closely as possible. 161 162 *Inclusion criteria* 163 Patients were included in the emulated trial if they met the inclusion criteria of the hypothetical 164 165 target trial and had not yet been administratively censored. As a single patient may meet the 166 eligibility criteria on multiple occasions, we emulated not a single trial, but four trials 167 sequentially, starting at months 12, 24, 36, and 48 after BC diagnosis, respectively. A patient 168 could be included in several of these emulated trials, as long as she met the inclusion criteria 169 on the month of trial onset. 170 171 *Treatment assignment* 172 173 For each of the four emulated trials, patients meeting the inclusion criteria were classified as 174 initiating VET if they redeemed at least two prescriptions of VET in the 12 months after 175 inclusion, and before relapse or death. The 12-month period during which patients were 176 permitted to initiate VET is referred to as the grace period. VET delivery was identified based on the outpatient delivery of estriol or promestriene, presented either as cream or vaginal ovules 177

178	(Supplementary Table 1). The control group comprised patients who were not delivered VET
179	in the year after inclusion in the emulated trial. Patients with a single VET delivery were
180	considered to have neither initiated nor refrained from having initiated the treatment and were
181	not included in either arm of the emulated trials.
182	
183	Oncological outcome
184 185	The oncological outcome was disease free survival (DFS), as defined in the hypothetical trial.
186	Relapses were identified from the treatments received and the conditions recorded during
187	hospitalizations stays (Supplementary Notes and Supplementary Table 2). All patients were
188	administratively censored on March 1, 2019, and administrative censoring was assumed to be
189	non-informative.
190	
191	Covariates
192	
193	Covariates could either be measured once, at the time of BC diagnosis and initial treatment, in
193 194	Covariates could either be measured once, at the time of BC diagnosis and initial treatment, in which case they were fixed for a single patient across all emulated trials, or they could be
193 194 195	Covariates could either be measured once, at the time of BC diagnosis and initial treatment, in which case they were fixed for a single patient across all emulated trials, or they could be measured repeatedly at the time of inclusion for each of the emulated trials, in which case they
193 194 195 196	Covariates could either be measured once, at the time of BC diagnosis and initial treatment, in which case they were fixed for a single patient across all emulated trials, or they could be measured repeatedly at the time of inclusion for each of the emulated trials, in which case they could vary for a single patient across all emulated trials. Covariates measured once included
193 194 195 196 197	Covariates could either be measured once, at the time of BC diagnosis and initial treatment, in which case they were fixed for a single patient across all emulated trials, or they could be measured repeatedly at the time of inclusion for each of the emulated trials, in which case they could vary for a single patient across all emulated trials. Covariates measured once included the (1) number of general practitioner visits, (2) number of gynecologist visits, and (3)
193 194 195 196 197 198	Covariates could either be measured once, at the time of BC diagnosis and initial treatment, in which case they were fixed for a single patient across all emulated trials, or they could be measured repeatedly at the time of inclusion for each of the emulated trials, in which case they could vary for a single patient across all emulated trials. Covariates measured once included the (1) number of general practitioner visits, (2) number of gynecologist visits, and (3) performance of mammography screening in the year before BC diagnosis; (4) deprivation level
 193 194 195 196 197 198 199 	Covariates could either be measured once, at the time of BC diagnosis and initial treatment, in which case they were fixed for a single patient across all emulated trials, or they could be measured repeatedly at the time of inclusion for each of the emulated trials, in which case they could vary for a single patient across all emulated trials. Covariates measured once included the (1) number of general practitioner visits, (2) number of gynecologist visits, and (3) performance of mammography screening in the year before BC diagnosis; (4) deprivation level of the area of residence and (5) enrollment in universal health insurance at BC diagnosis; (6)
 193 194 195 196 197 198 199 200 	Covariates could either be measured once, at the time of BC diagnosis and initial treatment, in which case they were fixed for a single patient across all emulated trials, or they could be measured repeatedly at the time of inclusion for each of the emulated trials, in which case they could vary for a single patient across all emulated trials. Covariates measured once included the (1) number of general practitioner visits, (2) number of gynecologist visits, and (3) performance of mammography screening in the year before BC diagnosis; (4) deprivation level of the area of residence and (5) enrollment in universal health insurance at BC diagnosis; (6) BC subtype, (7) nodal status, (8) type of BC surgery, (9) use of axillary surgery, (10) type of
 193 194 195 196 197 198 199 200 201 	Covariates could either be measured once, at the time of BC diagnosis and initial treatment, in which case they were fixed for a single patient across all emulated trials, or they could be measured repeatedly at the time of inclusion for each of the emulated trials, in which case they could vary for a single patient across all emulated trials. Covariates measured once included the (1) number of general practitioner visits, (2) number of gynecologist visits, and (3) performance of mammography screening in the year before BC diagnosis; (4) deprivation level of the area of residence and (5) enrollment in universal health insurance at BC diagnosis; (6) BC subtype, (7) nodal status, (8) type of BC surgery, (9) use of axillary surgery, (10) type of hospital for surgery, (11) use of radiotherapy and (12) chemotherapy setting during initial BC
 193 194 195 196 197 198 199 200 201 202 	Covariates could either be measured once, at the time of BC diagnosis and initial treatment, in which case they were fixed for a single patient across all emulated trials, or they could be measured repeatedly at the time of inclusion for each of the emulated trials, in which case they could vary for a single patient across all emulated trials. Covariates measured once included the (1) number of general practitioner visits, (2) number of gynecologist visits, and (3) performance of mammography screening in the year before BC diagnosis; (4) deprivation level of the area of residence and (5) enrollment in universal health insurance at BC diagnosis; (6) BC subtype, (7) nodal status, (8) type of BC surgery, (9) use of axillary surgery, (10) type of hospital for surgery, (11) use of radiotherapy and (12) chemotherapy setting during initial BC treatment. Covariates measured repeatedly included (1) endocrine therapy regimen, (2)

trial inclusion, and (5) age at trial inclusion. Further details on the definition of covariates areprovided in the Supplementary Notes.

- 206
- 207 208

Statistical analysis

209 Unlike the hypothetical target trial, treatment assignment in the observed data was not 210 randomized and could depend on a patient's characteristics, potentially leading to confounding. 211 Without appropriate adjustment, the study would also be subject to immortal-time bias due to 212 the 12-month grace period allowed between inclusion and VET initiation. To address both 213 confounding and immortal-time bias, we cloned each trial participant into two exact copies 214 (clones) [31,32]. One clone was assigned to the treatment arm, the other to the control arm. 215 Clones were artificially censored when their observed trajectories deviated from the treatment 216 strategy of the arm to which they were assigned. This informative artificial censoring 217 introduces selection bias over time, which was addressed by the use of time-varying inverse 218 probability of censoring (IPC) weights, estimated from the covariates. Standardized mean 219 differences (SMDs) were derived to assess adjustment quality after IPC weighting.

220 The ATE of VET initiation was estimated by the three-year and five-year differences in DFS 221 on the IPC-weighted population and was visually assessed by weighted Kaplan-Meier survival 222 curves. We intentionally reported outcomes on the survival scale to avoid the problems 223 associated with the causal interpretation of hazard ratios [31,33]. We conducted subgroup 224 analyses by HR status (HR-positive/HR-negative) and endocrine therapy regimen 225 (tamoxifen/aromatase inhibitors), and we analyzed the two molecules used as VET 226 (estriol/promestriene) both combined and separately. We performed a sensitivity analysis to 227 assess potential residual confounding bias, using fosfomycin, a first-line antibiotic used in the 228 treatment of urinary tract infections (UTIs) as a negative control exposure [34]. Fosfomycin 229 emerged as a suitable candidate for a negative control, because vaginal dryness and UTIs are

- both GSMs that could be induced by hypoestrogenic state [35], suggesting a common
 confounding structure of VET and fosfomycin, and because there was no prior evidence that
 fosfomycin could affect BC outcomes.
- 233
- 234 In a supplementary analysis, we adopted a methodology similar to previously proposed
- approaches [23], utilizing a time-dependent Cox proportional hazards regression model to
- estimate hazard ratios (HRs). Further details are provided in the Supplementary Notes and in
- 237 Supplementary Table 3.

238 **Results**

240

239 *Patients' characteristics*

Overall, 136,408 patients with previous BC met the inclusion criteria for at least one of the emulated trials, representing 373,568 patient-years in the aggregated analysis (Supplementary Figure 1). Of them, 1,737 patients ($1\cdot3\%$), representing 1,739 patient-years, initiated VET (Supplementary Table 4). Most patient-years who initiated VET received only promestriene ($55\cdot5\%$), while 34.6% received only estriol, and 9.9% received both promestriene and estriol (Supplementary Figure 2A). The median number of VET deliveries was 3 (IQR 2-6, Supplementary Figure 2B).

248

249 When compared with patients who did not initiate VET, patients who initiated VET were 250 slightly older at BC diagnosis (mean age 54.9 versus 54.0), resided in less deprived areas and 251 had more frequent visits to their general practitioner and gynecologist during the year preceding BC diagnosis (Table 1). Overall, BC subtype was mostly luminal (77.3%) while TNBC 252 253 (10.9%) and *HER2*-positive BC subtypes (*HR*-positive 7.6%; *HR*-negative 4.2%) were less 254 frequent, and this distribution was not different between patients who initiated VET and 255 patients who did not initiate VET. Regarding covariates measured repeatedly, patient-years 256 who initiated VET were more frequently treated with AI at trial inclusion (65.0% versus 57.9%257 of patients with HR-positive tumors) while less frequently treated with tamoxifen 258 (Supplementary Table 5).

259

After adjustment by IPC weighting, all SMDs were below 0.1 in absolute value (Supplementary Figure 3), suggesting that the statistical procedure enabled effective balancing of the characteristics between the group initiating VET and not initiating it. The estimated IPC weights at the end of the 12-month grace period ranged from 1.28 to 3.29 (median 2.04,

interquartile range IQR 1·84-2·31, Supplementary Figure 4). The median follow-up was 33
months (IQR: 16-50).

- 266
- 267 268

Effect of VET initiation on DFS

269 In the whole population, the estimated difference in DFS of VET initiation versus no initiation 270 was 0.3 percentage-point at three years (95% CI -1.1 to 1.4) and -1.5 at five years (95% CI -271 3.7 to 0.6) (Figure 1A, Table 2). In patients with HR-positive tumors, the estimated difference 272 at five years was -1.9 (95% CI -4.6 to 0.3, Figure 1B). We further subcategorized patients with 273 HR-positive tumors by ET regimen. In patients treated with AIs, the estimated difference in 274 DFS was -0.6 percentage-point at three years (95% CI -2.6 to 0.9), and -2.9 at five years (95% 275 CI -6.5 to 0.0) (Figure 1C). Conversely, in patients treated with tamoxifen, the estimated 276 difference in DFS was 2.2 percentage-points at three years (95% CI 0.4 to 3.7) and 0.2 at five years (95% CI -4.1 to 3.6, Figure 1D). In patients with HR-negative tumors, the estimated 277 difference was 0.3 percentage-point at three years (95% CI -3.4 to 3.9) and 1.9 at five years 278 279 (95% CI -2.4 to 6.7) (Figure 1E).

- 280
- 281 282

Effect of VET initiation on DFS according to the VET molecule

The estimated differences in DFS of promestriene initiation *versus* no VET initiation are displayed in Figure 2. In patients with HR-positive tumors treated with AI, the estimated difference in DFS was 1.0 percentage-point at three years (95% CI -1.0 to 2.6) and -2.5 percentage-points at five years (95% CI -6.7 to 1.1) (Figure 2C, Table 2).

287

The estimated differences in DFS of estriol initiation *versus* no VET initiation are displayed in Figure 3. Among patients with HR-positive disease currently treated with AIs, the estimated difference in DFS was -4·1 percentage-points at three years (95% CI -9·1 to -0·2) and -3·7 at

291	five years (95% CI -10·1 to 1·8) (Figure 3C); while it was 3·8 percentage-points at three years
292	(95% CI 1·2 to 5·7) and 4·0 at five years (95% CI -2·8 to 8·8) among patients currently treated
293	with tamoxifen (Figure 3D).

- 294
- 295 296

Negative control exposure

We analyzed fosfomycin initiation as a negative control exposure. The estimated difference in DFS for fosfomycin initiation *versus* no initiation was low in the whole population, and in patients with *HR*-positive tumors, regardless of their endocrine therapy regimen, both at three and five years (Supplementary Tables 6-7, Supplementary Figure 5). However, the estimated difference in DFS was 4·7 percentage-points (95% CI 0·8 to 7·8) at five years in patients with *HR*-negative tumors (Supplementary Figure 5E).

303

305

304

Comparison with a time-dependent Cox model

In a supplementary analysis mimicking an associational method previously proposed,[23] the estimated HR of VET initiation *versus* no initiation was 0.95 (95% CI 0.89-1.00) in the whole population, 0.96 (95% CI 0.82-1.12) in the subgroup of patients treated with tamoxifen, and 0.93 (95% CI 0.87-1.00) in the subgroup of patients treated with aromatase inhibitors (Supplementary Table 3).

311 **Discussion**

We emulated target trials investigating the effect of VET initiation on the risk of relapse or death in patients with non-metastatic BC. We found an increased risk of relapse of 2.9percentage-points at five years among patients initiating VET while treated by AI, notably in patients who initiated estriol.

316

317 Previous studies on VET use after BC provided reassuring results (Supplementary Table 8). 318 None found an adverse association between the use of VET and overall survival (OS) 319 [20,21,25], BC-specific survival [20–23], or DFS [17–21,25] in the broad population of BC survivors. On the contrary, some reported that VET use is associated with improved OS [25], 320 321 BC-specific survival [21,23], or DFS [21]. In particular, in the largest study so far, McVicker 322 et al [23] analyzed BC-specific survival according to VET use in a cohort of 49,237 women 323 with BC aged between 40 and 79 years. The authors found that VET use was associated with 324 a decrease in specific mortality (HR 0.77, 95% CI 0.63 to 0.94) in the overall population, but 325 also in the subgroup of patients treated with AIs (HR 0.72, 95% CI 0.58 to 0.91). In contrast, 326 a Danish observational study reported VET use to be associated with an increased risk of 327 recurrence in this subgroup (HR 1.39, 95% CI 1.04 to 1.85) [25].

328

All the previous observational studies are difficult to interpret causally and are prone to bias because they did not apply formal causal inference methods. In our work, by explicitly emulating a target trial, we have a straightforward causal interpretation of our results under explicit assumptions. In contrast, earlier investigations relied on traditional associational methods, estimating HRs from time-fixed or time-varying Cox models in cohort designs [18,20,21,23–25], or odds ratios (ORs) from logistic regression models in case-control designs [17,22]. These methods do not provide valid causal estimates, as shown in our supplementary

336 analysis where, by mimicking the methodology used in a previous study [23], we estimated the 337 HR in the AI group to be 0.93 (95% CI 0.87-1.00), in the opposite direction to the results we 338 obtained in our main analysis. Several reasons may explain this difference [32,36]. First, 339 traditional methods cannot account for treatment-confounding feedback due to time-varying 340 confounders [37–40]. In contrast, in our main analysis, we handled time-varying confounding 341 factors by emulating multiple target trials sequentially, treating time-varying confounding 342 factors as time-fixed confounders at each trials' baseline. Second, HRs and ORs are not 343 collapsible, which implies that the covariate-adjusted HRs from the previous observational 344 studies are substantially different quantities than the HRs estimated in randomized clinical 345 trials [33]. More broadly, there are concerns about the causal interpretation of HRs [31]. This 346 justifies why we have only presented results at the survival scale. Third, traditional time-fixed 347 methods are susceptible to immortal-time bias, arising when a grace period for treatment 348 initiation leads to a spurious overestimation of the protective effect of treatment [41]. We 349 avoided the bias by a cloning and weighting approach. Finally, any observational study might 350 be prone to bias due to unmeasured confounding. Unlike previous studies, we used a negative control exposure, fosfomycin, to detect potential residual confounding bias. The negative 351 352 control analysis did not detect evidence of unmeasured confounding in any subgroup, except 353 HR-negative tumors. Thus, we warrant caution in interpreting results pertaining to the HR-354 negative group. Conversely, the results of the negative control exposure analysis support a 355 causal interpretation of our findings in the remaining subgroups.

356

Overall, in the current study, no harmful effect of VET was detected marginally, in the overall population. However, among patients with HR-positive tumors, the effect of VET initiation on DFS was different according to ET regimen, with a transient protective effect of VET initiation in patients under tamoxifen at three years, not confirmed at five years; and a deleterious effect

361 of VET initiation in patients under AI at five years. Several randomized trials have reported 362 transient increases in circulating estrogen levels associated with the use of VET [12,42], with 363 systemic passage potentially exacerbated by vaginal atrophy [16]. Tamoxifen, a selective 364 estrogen receptor modulator, competes with estrogens and their derivatives with a higher 365 affinity for the estrogen-receptor, resulting in the inhibition of estrogen oncogenic pathway, 366 thereby counteracting the effects of small increases in circulating estrogen levels [43]. The 367 increase in DFS at three years observed in patients initiating VET while on tamoxifen could be 368 due to improved adherence to endocrine therapy, but further research is needed to validate this 369 hypothesis. Conversely, AIs inhibit estrogen production to nearly undetectable circulating 370 levels by inhibiting the conversion of adrenal androgens to estrogens [44]. With results 371 suggesting that long-term sharp estrogen deprivation may cause a hypersensitivity of estrogen 372 receptors in the breast [16], even a modest increase in estrogen levels in patients treated with 373 AIs could promote cancer recurrence.

374

375 Among AI-treated patients, we observed decrease in DFS in patients initiating estriol at three 376 years, but not in patients initiating promestriene. Several previous studies suggested that the 377 systemic passage of VETs may vary by molecule, with promestriene exhibiting limited systemic absorption [45]. Promestriene has a favorable safety profile with no alteration of 378 379 plasmatic levels of gonadotrophins or estradiol [46,47] while variations were found with estriol 380 [14,48], no stimulation of endometrium [49], and a pharmacological specificity with the 381 presence of 3-propyl and 17b-methyl ether groups making it less able to penetrate the basal 382 membrane.

383

384 We report here the largest study from far on the effect of VET initiation on oncological 385 outcomes. While we used state-of-the-art causal inference methodology, our study has

limitations. Firstly, our data do not allow assessment of over-the-counter purchases such as non-hormonal vaginal moisturizers, estradiol vaginal rings or prasterone. Secondly, we were not able to provide data on patients currently treated with gonadotropin-releasing hormone (gnRH) agonists together with AI or tamoxifen, due to the timeframe of the study, where these combinations were not yet standard of care. Finally, we were unable to draw conclusions for the subgroup of patients with *HR*-negative tumors due to potential residual unmeasured confounding, highlighting an area for future research.

393

In conclusion, our study suggests that VET initiation during BC follow-up could be safely proposed to patients with HR-positive tumors currently treated with tamoxifen. In patients currently treated with AIs, VET initiation should be avoided as much as possible until mature additional data are available. In the absence or after failure of non-hormonal alternatives, promestriene should be preferred over estriol in this subgroup. In a context of a growing number of patients are treated under AI notably with gnRH agonists, the development of novel efficient non hormonal therapies to alleviate GSM remains a burning unmet need.

401 **References**

- 402 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global
- 403 Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 404 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.
- 2. Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on
 plasma estradiol levels. Climacteric. 2015;18:121–34.
- 407 3. Sousa MS, Peate M, Jarvis S, Hickey M, Friedlander M. A clinical guide to the
- 408 management of genitourinary symptoms in breast cancer survivors on endocrine therapy.
 409 Ther Adv Med Oncol. 2017;9:269–85.
- 410 4. Pitkin J. BMS Consensus statement. Post Reprod Health. 2018;24:133–8.
- 411 5. Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women's midlife health
- 412 and menopause hormone therapy. Climacteric. 2016;19:109–50.
- 413 6. Del Pup L, Di Francia R, Cavaliere C, Facchini G, Giorda G, De Paoli P, et al.
- 414 Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it415 safe even in cancer patients? Anti-Cancer Drugs. 2013;24:989–98.
- 416 7. "The 2022 Hormone Therapy Position Statement of The North American Menopause
- 417 Society" Advisory Panel. The 2022 hormone therapy position statement of The North
- 418 American Menopause Society. Menopause. 2022;29:767–94.
- 8. Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-dependent
 Breast Cancer: Clinical Consensus. Obstetrics & Gynecology. 2021;138:950–60.
- 421 9. Hocké C, Diaz M, Bernard V, Frantz S, Lambert M, Mathieu C, et al. [Genitourinary
- menopause syndrome. Postmenopausal women management: CNGOF and GEMVi clinical
 practice guidelines]. Gynecol Obstet Fertil Senol. 2021;49:394–413.
- 424 10. Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, et al. 5th
- 425 ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals 426 of Oncology. 2020;31:1623–49.
- 11. Poggio F, Del Mastro L, Bruzzone M, Ceppi M, Razeti MG, Fregatti P, et al. Safety of
 systemic hormone replacement therapy in breast cancer survivors: a systematic review and
 meta-analysis. Breast Cancer Res Treat. 2022;191:269–75.
- 430 12. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: Vaginal estradiol appears to be431 contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Annals of
- 432 Oncology. 2006;17:584–7.
- 433 13. Wills S, Ravipati A, Venuturumilli P, Kresge C, Folkerd E, Dowsett M, et al. Effects of
- 434 Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Breast Cancer Survivors
- and Women at Risk of Breast Cancer Taking an Aromatase Inhibitor or a Selective Estrogen
- 436 Receptor Modulator. JOP. 2012;8:144–8.

- 437 14. Donders G, Neven P, Moegele M, Lintermans A, Bellen G, Prasauskas V, et al. Ultra-
- 438 low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor®) for vaginal
- 439 atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic,
- 440 safety, and efficacy phase I clinical study. Breast Cancer Res Treat. 2014;145:371-9.
- 441 15. Goldfarb SB, Dickler M, Dnistrian A, Patil S, Dunn L, Chang K, et al. Limited absorption of low dose 10μg intravaginal 17-β Estradiol (Vagifem®) in postmenopausal women with
- 442 443 breast cancer on aromatase inhibitors. Cancer Research. 2012;72.
- 444 16. Biglia N, Peano E, Sgandurra P, Moggio G, Panuccio E, Migliardi M, et al. Low-dose
- 445 vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a
- 446 preliminary study. Gynecological Endocrinology. 2010;26:404-12.
- 17. Le Ray I, Dell'Aniello S, Bonnetain F, Azoulay L, Suissa S. Local estrogen therapy and 447 448 risk of breast cancer recurrence among hormone-treated patients: a nested case–control study. 449 Breast Cancer Res Treat. 2012;135:603-9.
- 450 18. Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in 451 women previously treated for breast cancer. Climacteric. 2003;6:45-52.
- 452 19. Vassilopoulou-Sellin R, Theriault R, Klein MJ. Estrogen replacement therapy in women 453 with prior diagnosis and treatment for breast cancer. Gynecol Oncol. 1997;65:89–93.
- 454 20. O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone
- 455 Replacement Therapy After a Diagnosis of Breast Cancer in Relation to Recurrence and
- 456 Mortality. Journal of the National Cancer Institute. 2001;93:9.
- 457 21. Durna EM, Leader LR, Sjoblom P, Eden JA, Wren BG, Heller GZ. Hormone replacement 458 therapy after a diagnosis of breast cancer: cancer recurrence and mortality. Medical Journal
- 459 of Australia. 2002;177:347-51.
- 460 22. Sund M, Garmo H, Andersson A, Margolin S, Ahlgren J, Valachis A. Estrogen therapy 461 after breast cancer diagnosis and breast cancer mortality risk. Breast Cancer Res Treat. 462 2023;198:361-8.
- 23. McVicker L, Labeit AM, Coupland CAC, Hicks B, Hughes C, McMenamin Ú, et al. 463 464 Vaginal Estrogen Therapy Use and Survival in Females With Breast Cancer. JAMA Oncol.
- 465 2023;e234508.
- 466 24. Agrawal P, Singh SM, Able C, Dumas K, Kohn J, Kohn TP, et al. Safety of Vaginal 467 Estrogen Therapy for Genitourinary Syndrome of Menopause in Women With a History of Breast Cancer. Obstet Gynecol. 2023;142:660-8. 468
- 469 25. Cold S, Cold F, Jensen M-B, Cronin-Fenton D, Christiansen P, Ejlertsen B. Systemic or 470 Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study. 471 JNCI: Journal of the National Cancer Institute. 2022;djac112.
- 472 26. Hernán MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized 473 Trial Is Not Available. Am J Epidemiol. 2016;183:758-64.
- 474 27. Maringe C, Benitez Majano S, Exarchakou A, Smith M, Rachet B, Belot A, et al.
- 475 Reflection on modern methods: trial emulation in the presence of immortal-time bias.

- 476 Assessing the benefit of major surgery for elderly lung cancer patients using observational data. International Journal of Epidemiology. 2020;49:1719-29. 477
- 478 28. Tuppin P, Rudant J, Constantinou P, Gastaldi-Ménager C, Rachas A, de Roquefeuil L, et 479 al. Value of a national administrative database to guide public decisions: From the système
- 480 national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système
- 481 national des données de santé (SNDS) in France. Rev Epidemiol Sante Publique. 2017;65
- 482 Suppl 4:S149-67.
- 483 29. Bousquet PJ, Lefeuvre D, Tuppin P, BenDiane MK, Rocchi M, Bouée-Benhamiche E, et
- 484 al. Cancer care and public health policy evaluations in France: Usefulness of the national
- 485 cancer cohort. PLoS One. 2018;13:e0206448.
- 486 30. Dumas E, Laot L, Coussy F, Grandal Rejo B, Daoud E, Laas E, et al. The French Early
- 487 Breast Cancer Cohort (FRESH): A Resource for Breast Cancer Research and Evaluations of 488 Oncology Practices Based on the French National Healthcare System Database (SNDS).
- 489 Cancers. 2022;14:2671.
- 490 31. Stensrud MJ, Hernán MA. Why Test for Proportional Hazards? JAMA. 2020;323:1401-491 2.
- 492 32. Hernán MA, Sauer BC, Hernández-Díaz S, Platt R, Shrier I. Specifying a target trial
- 493 prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin 494 Epidemiol. 2016;79:70-5.
- 495 33. Stensrud MJ, Aalen JM, Aalen OO, Valberg M. Limitations of hazard ratios in clinical 496 trials. European Heart Journal. 2019;40:1378-83.
- 497 34. Lipsitch M, Tchetgen ET, Cohen T. Negative Controls: A Tool for Detecting 498 Confounding and Bias in Observational Studies. Epidemiology. 2010;21:383-8.
- 499 35. Flores SA, Hall CA. Atrophic Vaginitis. StatPearls [Internet]. Treasure Island (FL):
- 500 StatPearls Publishing; 2023 [cited 2023 Nov 29]. Available from:
- 501 http://www.ncbi.nlm.nih.gov/books/NBK564341/
- 36. Dickerman BA, García-Albéniz X, Logan RW, Denaxas S, Hernán MA. Emulating a 502
- 503 target trial in case-control designs: an application to statins and colorectal cancer. 504 International Journal of Epidemiology. 2020;49:1637-46.
- 505 37. Hernán MA, Robins JM. Causal Inference: What If. Boca Raton: Chapman&Hall/CRC. 506 2020.
- 507 38. Robins J. A new approach to causal inference in mortality studies with a sustained
- 508 exposure period—application to control of the healthy worker survivor effect. Mathematical 509 Modelling. 1986;7:1393-512.
- 39. Robins JM, Hernan MA, Brumback B. Marginal Structural Models and Causal Inference 510 511 in Epidemiology. Epidemiology. 2000;11:550-60.
- 40. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal 512
- 513 effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11:561-70.

- 514 41. Suissa S. Immortal Time Bias in Pharmacoepidemiology. American Journal of
- 515 Epidemiology. 2008;167:492–9.
- 516 42. Sánchez-Rovira P, Hirschberg AL, Gil-Gil M, Bermejo-De Las Heras B, Nieto-Magro C.
- 517 A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter
- 518 Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-
- 519 Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with
- 520 Aromatase Inhibitor in the Adjuvant Setting. Oncologist. 2020;25:e1846-1854.
- 521 43. Riggs BL, Hartmann LC. Selective Estrogen-Receptor Modulators Mechanisms of
- 522 Action and Application to Clinical Practice. New England Journal of Medicine.
- 523 2003;348:618–29.
- 44. Miller WR. Aromatase inhibitors: mechanism of action and role in the treatment of breastcancer. Semin Oncol. 2003;30:3–11.
- 45. Santos I, Clissold S. Urogenital disorders associated with oestrogen deficiency: the role of
 promestriene as topical oestrogen therapy. Gynecological Endocrinology. 2010;26:644–51.
- 46. Wolff JP, Cachelou R, Guéritée N. Absence of systemic hormonal effects in an oestradiol
 diether topically active on the vaginal mucosa. Maturitas. 1982;4:239–46.
- 47. Campana G, Di Grancesco null. [Climacteric syndrome : clinical experiences using
 promestriene]. Ann Ostet Ginecol Med Perinat. 1976;97:189–97.
- 532 48. Pfeiler G, Glatz C, Königsberg R, Geisendorfer T, Fink-Retter A, Kubista E, et al.
- 533 Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients.
- 534 Climacteric. 2011;14:339–44.
- 49. Sun A, Lin S, Jing L, Wang Z, Ye J, Zhang Y. [Safety of promestriene capsule used in
 postmenopausal atrophic vaginitis]. Zhonghua Fu Chan Ke Za Zhi. 2009;44:593–6.
- 537

Tables

		No VET	Any VET
Number of patients		133205	1737
Soci	o-economic factors		
Age at BC diagnosis		54·0 (9·5)	54·9 (8·4)
	1st quintile (least deprived)	25099 (18·8)	414 (23·8)
	2nd quintile	26457 (19·9)	340 (19·6)
Denni setien inden	3rd quintile	26020 (19·5)	324 (18·7)
Deprivation index	4th quintile	26365 (19·8)	320 (18·4)
	5th quintile (most deprived)	26637 (20·0)	298 (17·2)
	Overseas departments	2627 (2·0)	41 (2·4)
	0	8688 (6·5)	75 (4·3)
	1-5	69124 (51·9)	812 (46·7)
	6-11	40699 (30·6)	574 (33·0)
	12+	14694 (11·0)	276 (15·9)
	0	67235 (50·5)	733 (42·2)
C	1	39471 (29.6)	536 (30·9)
Gynecologist visits***	2-3	22138 (16.6)	378 (21.8)
	4+	4361 (3.3)	90 (5·2)
	No	125157 (94.0)	1657 (95.4)
Enrollment in universal health insurance	Yes	8048 (6.0)	80 (4.6)
BC diagnos	tic, biology, and treatment	· ·	•••
Mammagraphia seregaring before DC diagnosis	No	81645 (61·3)	1018 (58·6)
Mammographic screening before BC diagnosis	Yes	51560 (38.7)	719 (41.4)
	luminal	102977 (77·3)	1367 (78·7)
PC subtures	TNBC	14492 (10·9)	181 (10·4)
BC Subtype	HER2+/HR+	10176 (7·6)	127 (7·3)
	HER2+/HR-	5560 (4·2)	62 (3·6)
HR status	HR -positive	113153 (84·9)	1494 (86·0)
	HR -negative	20052 (15·1)	243 (14·0)
	Node-negative	102328 (76·8)	1389 (80·0)
Nodal status	Node-positive	30877 (23·2)	348 (20·0)
	Lumpectomy	98061 (73·6)	1354 (78·0)
Type of BC surgery	Mastectomy	35144 (26·4)	383 (22·0)
	No	10201 (7.7)	155 (8·9)
Axillar surgery	Yes	123004 (92·3)	1582 (91·1)
	CLCC	36537 (27.4)	480 (27·6)
	Non profit private hospitals	4639 (3·5)	54 (3·1)
Type of nospital for surgery	Profit private hospitals	55408 (41.6)	776 (44.7)
	Public hospitals	36621 (27.5)	427 (24·6)
Dedicthermony	No	10019 (7.5)	122 (7.0)
kadiotherapy	Yes	123186 (92.5)	1615 (93.0)
Chamath ann an	No	58983 (44·3)	806 (46·4)
chemotherapy	Yes	74222 (55.7)	931 (53·6)
Setting	Adjuvant	59074 (79·6)	762 (81·8)
	Neo-adjuvant	13678 (18·4)	148 (15·9)
	Both	1470 (2·0)	21 (2.3)

Table 1: Patient's characteristics by VET initiation status for all variables measured at the time of BC diagnosis and initial treatments. Patients were assigned to the "Any VET" group

if they were classified as patients initiating VET in at least one of the four emulated trials; otherwise, they were assigned to the "No VET" group. The number of patients, and the percentage of patients (in parentheses), are reported for categorical variables. The mean value, and the standard deviation (in parentheses), are reported for continuous variables. Of note: of the 136,408 patients meeting the inclusion criteria for at least one of the emulated trials, 1,466 patients received VET only once during the grace period for at least one of the emulated trials, and were artificially censored from both arms for this trial. They are not shown in this table for the sake of simplicity. *Number of general practitioner (GP) visits in the year preceding BC diagnosis. **Number of gynecologist visits in the year preceding BC diagnosis. VET: vaginal estrogen therapy; GP: general practitioner; BC: breast cancer; TNBC: triple-negative breast cancer; CLCC: "Centre de Lutte Contre le Cancer" (center for the fight against cancer); HR: hormone receptor; HER2: human epidermal growth factor receptor 2.

		HR- positive						
	Whole population	All	Currently treated with Al	Currently treated with tamoxifen	HR -negative			
VET initiation versus no VET initiation								
3 years	0·3 (-1·1 to 1·4)	0·3 (-1·2 to 1·3)	-0·6 (-2·6 to 0·9)	2·2 (0·4 to 3·7)	0·3 (-3·4 to 3·9)			
5 years	-1·5 (-3·7 to 0·6)	-1·9 (-4·6 to 0·3)	-2·9 (-6·5 to 0)	0·2 (-4·1 to 3·6)	1·9 (-2·4 to 6·7)			
Promestriene initiation versus no VET initiation								
3 years	1 (-0·7 to 2·3)	1 (-0·8 to 2·4)	1 (-1 to 2·6)	1·5 (-1·1 to 3·8)	0·7 (-4·5 to 5)			
5 years	-2·1 (-5·2 to 0·5)	-2·6 (-6·2 to 0)	-2·5 (-6·7 to 1·1)	-2·3 (-8·7 to 2·4)	1·8 (-3·7 to 8·2)			
Estriol initiation versus no VET initiation								
3 years	-0·8 (-3·7 to 1·5)	-1 (-4·3 to 1·5)	-4·1 (-9·1 to -0·2)	3·8 (1·2 to 5·7)	0·9 (-4·6 to 6·4)			
5 years	0·2 (-3·9 to 3·7)	-0·7 (-5·4 to 3·3)	-3·7 (-10·1 to 1·8)	4 (-2·8 to 8·8)	5·1 (-0·1 to 11·2)			

2 3

1

Table 2: Difference in disease-free survival (DFS, in percentage-points) at three years and five years and associated 95% confidence intervals for

4 VET initiation versus no VET initiation, promestriene initiation versus no VET initiation, and estriol initiation versus no VET initiation for the

5 whole population and per subgroup. Abbreviations: VET: vaginal estrogen therapy; HR: hormone receptor; AI: aromatase inhibitor.

6 Figures



7

8

Figure 1: Effects of VET initiation on disease-free survival in the whole population of BC patients (A) and for subgroups defined by HR status
and endocrine therapy regimen (B-E). Abbreviations: VET: vaginal estrogen therapy; HR: hormone receptor; CI: confidence interval.



Figure 2: Effects of promestriene initiation on disease-free survival in the whole population of BC patients (A) and for subgroups defined by HR status and endocrine therapy regimen (B-E). Abbreviations: VET: vaginal estrogen therapy; HR: hormone receptor; CI: confidence interval.



Figure 3: Effects of estriol initiation on disease-free survival in the whole population of BC patients (A) and for subgroups defined by HR status and endocrine therapy regimen (B-E). Abbreviations: VET: vaginal estrogen therapy; HR: hormone receptor; CI: confidence interval.

Funding

This study was funded by Monoprix*, INCa grant number 18-127 within the COMBIMMUNO (Comedications and comorbidities in breast cancer: Deciphering Interactions Between Immune Infiltration, Response to Treatment and Prognosis) project, and the Swiss National Science Foundation. The funder was not involved in study design, or in the collection, analysis, and interpretation of data, the writing of this article or the decision to submit it for publication.

Competing interests

Christine Rousset-Jablonski reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events by Theramex (payment made to institution). Paul Gougis reports consulting fees for BMS, academic grant from Sanofi and travel accommodation by Eisai. Other authors have no relevant financial or non-financial interests to disclose.

Author Contributions

- (I) Project Conception: Ame-Sophie Hamy, Fabien Reyal, Florence Coussy.
- (II) Statistical Study design: Kerollos Nashat Wanis, Mats Julius Stensrud, Elise Dumas.
- (III) Data Provision and quality: Philippe-Jean Bousquet, Sophie Houzard, Christine Le Bihan-Benjamin.
- (IV) Medical support : Enora Laas, Floriane Jochum, Diane Hill, Christine Rousset-Jablonski, Sophie El Ferjaoui, Paul Gougis, Florence Coussy.
- (V) Data analysis and interpretation: Elise Dumas.
- (VI) Manuscript first draft: Elise Dumas, Mats Stensrud, Kerollos Wanis, Anne-Sophie Hamy, Florence Coussy.
- (VII) Manuscript writing: All authors.

(VIII) Final approval of manuscript: All authors.

Ethics approval

The study was conducted in collaboration between Institut Curie and the French National Cancer Institute (INCa), following institutional and ethical rules concerning research involving patient data, and was authorized by the French data protection agency (Commission nationale de l'informatique et des libertés—CNIL) under registration number 920017.

Consent to participate

In accordance with French regulations applicable to the SNDS, no informed consent was required because the data used in the study was de-identified.